GlassScriptPhysician profile
Tatyana Sergeyeva
NPI 1164599205
$2,145.96
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $76.83 · 2021: $34.37 · 2022: $227 · 2023: $462 · 2024: $745 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $268.94 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $239.11 | 2019-2025 | |
| Novo Nordisk INC | $189.39 | 2019-2024 | Rybelsus, Ozempic |
| Beta Bionics, INC. | $184.84 | 2023-2024 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.30 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $152.77 | 2020-2023 | Recorlev |
| Corcept Therapeutics | $139.09 | 2019-2025 | Korlym |
| Cequr Corporation | $103.23 | 2022-2024 | Cequr Simplicity |
| Abbvie INC. | $99.70 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $87.29 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $60.88 | 2022-2024 | Omnipod |
| Kyowa Kirin, INC. | $49.08 | 2024 | Crysvita |
| Medtronic, INC. | $48.58 | 2021-2023 | Minimed 780g |
| Abbott Laboratories | $45.03 | 2022-2024 | Freestyle Libre 2 |
| Lilly USA, LLC | $44.99 | 2024 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $35.29 | 2019-2020 | |
| Radius Health, INC. | $30.07 | 2024 | Tymlos |
| Janssen Pharmaceuticals, INC | $29.87 | 2020-2024 | Xarelto |
| Amneal Pharmaceuticals LLC | $27.54 | 2024 | Unithroid |
| Valeritas, INC. | $26.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2023 | |
| Zealand Pharma US, INC. | $19.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2019 | |
| Shire North American Group INC | $18.54 | 2019 | |
| Ascensia Diabetes Care US INC. | $16.17 | 2023 | |
| Horizon Therapeutics Plc | $15.65 | 2020 | |
| Amgen INC. | $12.87 | 2023 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatyana Sergeyeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.